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Introduction 
Continuous Ambulatory Peritoneal Dialysis (CAPD) was originally 
introduced by Popovich et al. in 1976, and since its introduction, it has 
offered better management of diabetic patients with End-Stage Renal 
Failure. In this context CAPD offers several medical advantages which 
include, steady-state control of uraemia, easier control of hypertension, 
stable cardiovascular status without rapid fluid shifts, and good tight 
control of blood sugar achieved by the intraperitoneal administration of 
insulin. Social advantages include, freedom from machine and electrical 
outlets, thereby enabling patients to travel extensively, no need to learn 
complex machinery and training time can be reduced to 10 - 15 days. 
In this project, four studies were conducted. The aims of the studies were 
to: 
Study 
Epidemiology 
A Investigate the trend in the incidence of chronic renal failure, and 
to establish, the frequency of the various causes of chronic renal 
failure, the stage of renal failure, and the method of treatment 
B Investigate the trend in the incidence of diabetic nephropathy as a 
cause of chronic renal failure and obtain an idea of the 
demographic characteristics of patients suffering from diabetic 
nephropathy. 
C Investigate and perform a retrospective record analysis of a 
group of diabetic patients and determine the rate and extent of 
diabetic nephropathy, and obtain an idea of the demographic 
characteristics of these patients. 
Study 2 
A i) Determine patient and technique survival of patients 
with End-Stage Renal Failure (ESRF) newly treated by 
CAPD 
i i) Determine the frequency and causes of complications, 
particularly peritonitis and catheter-related difficulties 
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iii) Evaluate the inpatient and outpatient support facilities 
required 
B Predict the time at which ESRF will develop in a group of 
patients, and treatment planned in advance. 
Study 3 
A Assess the quality of life of patients currently and previously on 
CAPD, and the impact which renal failure and subsequently CAPD 
on them, both psychologically and socially. 
Study 4 -
A Perform a cost-effectiveness study on the use of CAPD. 
Methodology 
Studyl 
Epidemiology 
Part A: The list of the number of patients suffering from chronic renal 
failure was obtained from the Renal Failure Registers kept at the 
Medical Out-Patients and at the Medical Ward M6. In addition the 
patients' confidential files kept at the Medical Records were reviewed to 
obtain necessary information on these patients such as age, sex, cause of 
chronic renal failure, year of onset of chronic renal failure, the method of 
treatment, together with the levels of Serum Creatinine and Blood Urea, 
investigated at several different points in the course of renal failure. 
Part B: The patients diagnosed as suffering from diabetic nephropathy 
took part in this study. For each patient two files were-reviewed: the 
Confidential File kept at the Medical Records, and the Diabetic file 
which is kept at the Diabetic clinic. Information collected from both 
files included: age, sex, year and age at onset of diabetes, duration of 
diabetic nephropathy till the end of December 1991, and levels of Serum 
Creatinine and Blood Urea investigated at several different points in the 
course of diabetes. 
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Part C: A group of 300 patients suffering from diabetes mellitus (Type I 
and Type II) were selected at random from the daily intake of patients at 
the Diabetic Clinic at St. Luke's Hospital during the period June to 
September 1991. When these patients visited the clinic, blood samples 
were taken to determine the levels of Serum Creatinine and Blood Urea. 
In addition the Confidential File and the Diabetic File were reviewed to 
obtain necessary information on them such as age, sex, year and age at 
onset of diabetes, duration of diabetes to date, the type of diabetes, and 
levels of Serum Creatinine and Blood Urea investigated at several 
different points in the course of renal failure. 
Study 2 
Clinical Aspects 
Part A: All patients who have used CAPD in Malta (n=6) took part in 
this study. The· patients' confidential files were reviewed to obtain 
certain information such as age, sex, year at initiation of CAPD till the 
end of December 1991, primary renal disease, reasons for choice of CAPD, 
complicating factors at start of therapy survival on CAPD, number and 
duration of hospital admissions and complications of CAPD including 
peri toni tis. 
Part B: The results of a number of patients (n=36, 14 males, 15 females) 
having a serum creatinine higher than 200umol/L but smaller than 
440umol/L (end-stage renal failure) were taken to plot a graph of the 
inverse of serum creatinine (1/Cr) versus time (months) for each patients. 
The predicted time at which the patient would require treatment by 
CAPD fOT.ESRF was determined by extrapolation at a serum creatinine of 
440umol/L. Observations were made only when serum creatinine levels 
were >200umol/L; below this value, small flactuations in creatinine 
produce large changes in 1/Cr. 
Study 3 
Quality of life of patients on CAPD 
Home visits were carried out three times on 3 successive months, and the 
patient interviewed tQgether with his family, a process which took on 
average one and a half hours. In the case of patients who died while on 
the technique, their relatives were interviewed to obtain as much 
information as necessary on the quality of life of the patients. 
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Study 4 
The results obtained in Study 2 were translated in financial 
considerations; these included the cost of the technique and of the 
antibiotics required for treatment of peritonitis; and of the hospital 
admissions of each patient. 
Results 
Study 1 
Part A: The 87 patients studied included 59.8% (n=52) males and 40.2% 
(n=35) females. The trend in the incidence of chronic renal failure over 
the period 1982 - 1991 is given in Table 1. 
Table 1: Trend in the incidence of Chronic Renal Failure over the period 
1982 -1991 
Year New patients Total No. of patients 
diagnosed with CRF 
1982 8 8 
1983 2 10 
1984 6 16 
1985 15 31 
1986 17 48 
1987 9 57 
1988 6 63 
1989 8 71 
1990 9 80 
1991 7 87 
The causes of chronic renal failure in the patients studied is given in 
Table 2. 
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Table 2: Trend in the cause of chronic renal failure during the period 1982 
-1991 
Cause No. of % Distribution 
cases 
Glomerulonephri tis 25 28.7 
Diabetic nephropathy 23 26.4 
Hypertension 13 15.0 
Polycystic kidney disease 8 92 
Miscellaneous and uncertain 19 21.8 
Chronic pyelonephritis 6 7.0 
Renal stones 2 2.3 
Carcinoma bladder 1 1.1 
Renal cell carcinoma 1 1.1 
Focal segmental 
glomerulosclerosis 1 1.1 
Renal colic 2 2.3 
Renal cyst 1 1.1 
Uncertain 5 5.8 
64% (n=56) of the patients were being managed by haemodialysis, 6.9% 
(n=6) with CAPO, while 9.2% (n=8) had a renal transplant. The rest 
19.5% (n=17) were managed by drug therapy. 
Part B: During the period 1982 - 1991, 23 patients were diagnosed as 
suffering from diabetic nephropathy, 8 100M and 15 NIDDM. These 
included 56.5% (n;=13) males and 43.5% (n=10) females. The patients haJ. 
a mean age of 60.7 (range 37 - 79) years. The incidence of diabetic 
nephropathy is given in Table 3. 
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Table 3: Year at onset of diabetic nephropathy in the patients studied 
Year Total % Distribu tion 
1982 2 8.7 
1983 1 4.4 
1984 1 4.4 
1985 3 13.0 
1986 2 8.7 
1987 4 17.4 
1988 3 13.0 
1989 3 13.0 
1990 3 13.0 
1991 1 4.4 
Table 4~ Stage of renal failure of diabetic nephropathy patients studied 
Creatinine level 
umol/L 
133 -440 
>440 
Total 
19 82.6% 
4 17.4% 
Males Females 
11 57.9% 
2 50.0% 
8 42.1% 
2 50.0% 
Part C: During the period June 1991 to September 1991, 300 Diabetic 
patients (113 males and 157 females) were studied. The patients had a 
mean age of 60.53 (range 14-86) years. The 300 patients included 20% 
(n=60) Type I IDDM and 80% (n=240) Type II NIDDM. The renal function 
of the patients studied is given in Table 5. 
Table 5: Renal function of the patients studied 
Serum creatinine level Total Males Females 
No. % No. No. 
Normal serum creatinine 235 116 119 
Elevated S.Creatinine 65 21.3 27 38 
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The age distribution of the whole group of patients had a mean of 62.8 
years. The ages ranged from 30 to 83 years. The duration of diabetes had 
a mean of 21.6 (range 1 - 45) years. The patients included 40% (n=26) 
100M and 60% (n=39) NIDDM. The mean duration of diabetes at the 
onset of renal failure is 21.48 (range 8 - 41) years. Of the patients studied, 
96.9% (n=63) were at the onset of renal failure, while 3.1 % (n=2) were at 
end-stage renal failure. 
Study 2 
Clinical aspects 
Part A: During the period 1988 - 1991, 6 patients started CAPO, median 
age 50.3 years (range 6 - 65). Patients had a mean duration of treatment of 
79.3 weeks (range 24 - 160). As for the primary renal disease, 33.3% (n=2) 
had glomerulonephritis, 16.7% (n=1) pyelonephritis, 33.3% (n=2) 
diabetes mellitus and 16.7% (n=1) polycystic kidney disease. 
Table 6: Reasons governing choice of therapy and complicating factors at 
start of therapy 
Pts. % 
Reasons governing choice of therapy 
Angina 1 16.7 
Myocardial infarction 1 16.7 
Heart failure 2 33.3 
Cerebrovascular disease 1 16.7 
Diabetes mellitus 2 33.3 
Renal unit policy 3 50.0 
Holding for transplant 1 16.7 
Complicating factors at start of therapy 
Angina 1 16.7 
Myocardial infarction 1 16.7 
Heart failure 2 33.3 
Cerebrovascular disease 2 33.3 
Diabetes mellitus 2 33.3 
An individual may have more than one positive reason for choice of 
therapy. Only the main reason for choice are given. 
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By the end of 1991, 2 patients (33.3%) were still on CAPD, 1 (16.7%) had 
a renal transplant, while 3 (50%) died (2 of cardiac complications and one 
of cerebrovascular complications). 
The average duration of hospital admissions was 14.9 days per patient-
year of therapy. Non-dialysis-related causes of admission (medical, 
surgical, social) was 9 days/patient-year. There were more admissions 
for peritonitis and catheter-related difficulties (5 and 2 days/patient-
year respectively). 
In the 6 CAPD patients there were 10 temporary modality changes, 10 
requiring hospital haemodialysis. Individual temporary changes lasted 
a mean of 20 days (range 5 - 63 days) amounting to an overall duration of 8 
days/patient-year of treatment. 
The overall peritonitis rate was 1.3 episodes/patient-year. 15 episodes 
were recorded. There was a cure in 80%, relapse in 13.3, and immediate 
catheter removal to effect a cure in 6.7%. 33.3% of all patient remained 
free of peritonitis. 
Part B: At the time the patients reached a serum creatinine of 200 umol/L 
their mean age was 61.2 (range 25 - 75) years and the mean duration of 
diabetes was 24.8 (range 14 - 48) years. 15 patients were IDDM (Insulin 
Dependant Diabetes Mellitus) while 21 patients were NIDDM (Non-
Insulin Dependant Diabetes Mellitus). The predicted year in which the 
patients studied will require CAPD, together with the number in each 
year is given in Table 7. 
Table 7: 
Year Number of Patients % 
1991 4 11.1 
1992 11 30.6 
1993 7 19.4 
1994 9 25.0 
1995 3 8.3 
1996 2 5.6 
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Study 3 
Quality of life of patients on CAPD 
The patients were suffering from a number of psychological and social 
problems. The most important included, a feeling of limitation, loss of 
body image, self-image and self-esteem, sensitivity to what other people 
say, adherence to the treatment, fear of snagging or pulling the catheter 
during sleep, fear of infection and feeling of death. 
The lifestyle of the patients was one of severe limitation, with the only 
'excursion' being the regular visit to the hospital. Passive recreation such 
as listening to the radio, reading newspapers, watching television or 
doing some little knitting or sewing in the case of the females were 
regarded as hobbies. Social participation was almost non-existant and 
patients were not inclined to participate in clubs or associations. From 
the families' point of view, a heavy burden was carried by the partner, 
who in the case of elderly patients, was far from fit, thus requiring a 
strong commitment. The patient frequently became demanding and 
irritable in a childish and dependant way, taking the partner's efforts 
for granted. Fortunately, the majority of families were able to cope. 
Study 4: 
The costings of a CAPO patient per year per annum is given in Table 8 
Table 8: Annual costings of a CAPO patient 
Item 
Technique 
Cost per episode of peritonitis 
Gram-positive organisms 
Gram-negative organisms 
Fungi 
Cost of hospital admissions 
Cost per annum per 
patient (Lm) 
3818.70 - 3898.80 *1 
60.99 - 388.50 
105.65 - 496.67 
11.34 
1434.00 
*1 Values range depending on whether the patient uses four 1.36% 
dextrose solutions daily, or three 1.36% dextrose and one 3.8% dextrose. 
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Thus, the total cost is Lm5,313.69 - Lm5,721.30 in case of Gram-positive 
organisms, Lm5,357.65 - Lm5,829.47 in case of Gram-negative and 
Lm5,264.04 - Lm5,344.14 in case of fungal organisms. These values take 
into account one episode of peritonitis per year and a rate of hospital 
admissions of 23.9 as determined in Study 2B. Consequently, these values 
vary according to the number of episodes of peritonitis, the drug 
combination used, and the number of admissions per year. 
Discussion 
Results show that diabetic nephropathy is the cause of renal failure in 
26.4% of the patients studied. This is a high proportion of patients for 
whom treatment, although costly, cannot be denied. Study 2 has shown 
that although CAPO has been established world-wide since 1976, it was 
only 12 years later that it was introduced in Malta. So far, six patients 
have used CAPO, with a survival rate of 40%. This is comparable to the 
early reports from the European Dialysis and Transplant Registry which 
stated a survival rate of 28% in 1980. In addition patients had an 
unacceptably high peritonitis rate of 1.3 episodes per patients year when 
compared to the rate of less than one episode per 24 patient months, on 
using the 'Y' system. Notwithstanding this, home visits have helped to 
reduce the psychological and social problems with the patients were 
experiencing. 
Conclusion 
This project has highlighted the initial difficulties of CAPO in Malta. 
The pharmacist's roles, which include providing direct patient care, 
counselling and support, as an educator, administrator, infection control 
agent and as a member of the multidisciplinary team will contribute to a 
higher success of CAPO in Malta. Finally, a booklet to help CAPO 
patients to master their technique and improve their quality of life 
while on CAPO, was devised. 
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